Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
CINME abre sus puertas en el 2007. Su misión es mejorar la calidad de vida de sus pacientes, a través de la atención médica asistencial humana e integral, siendo un centro educador para la comunidad y aportando datos cualitativos al avance científico en el marco de la investigación clínica. Hemos incorporado nuevas áreas terapéuticas en el campo de la salud, buscando ser en cada una un centro modelo para el diagnóstico y tratamiento de enfermedades, y al mismo tiempo de referencia en el campo de la investigación clínica. Teniendo como ideal la excelencia, hemos hecho especial énfasis en los procesos que nos aportan altos estándares de calidad en nuestro trabajo. Por ello, en el 2019 certificamos en calidad en los procesos de investigación clínica a través de IRAM-ISO 9001-2015.Viamonte 2278, CABA, Buenos Aires
Websitewww.cinme.com.ar
Select an option
I am a doctor
I am a sponsor
Specializations
Dermatitis atópica
Diabetes
Hepatitis autoinmune
Colitis ulcerosa
Enfermedad de Crohn
Fibrosis pulmonar
Fibrosis pulmonar idiopática
Cardiovascular
Nefropatía
Our team
Medical staff
Catalina Hermida
Daniel Seinhart
Yésica Castillo
Yessica Castillo
Federico Carlos Perez Manghi
Maria de Lourdes Figuerola
Gonzalo Saenz
María Margarita Anders
Estanislao Gómez
Alejandra Romeo
Angela Romero Zarante
Mónica Rondinón
Liliana González
Mariana Abal
Ricardo Galimberti
Maria Laura Galimberti
Griselda Russo
María Otaola
Adriana Ellenberg
Maria Otaola
Fernando Halac
Raquel Analia González
Estanislao Jesus Gomez
Mariana Paula Blas
Maria Otaola
Maria Julia Garay
Lucas Manghi
Gonzalo Saenz
Alberto Casey
Alberto Lorenzo Casey
Open studies
Cardiovascular disease
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels - REDEFINE 3 - Novo Nordisk A/SSee more
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease - TRIUMPH-3 - Eli Lilly and CompanySee more
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Obesity
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels - REDEFINE 3 - Novo Nordisk A/SSee more
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease - TRIUMPH-3 - Eli Lilly and CompanySee more
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity - Eli Lilly and CompanySee more
Diabetes
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity - Eli Lilly and CompanySee more
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) - Eli Lilly and CompanySee more
Lung cancer
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy - SKYSCRAPER-15 - Hoffmann-La RocheSee more
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) - GlaxoSmithKlineSee more
Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata - BRAVE-AA-PEDS - Eli Lilly and CompanySee more
Alzheimer disease
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease - PROGRESS-AD - GlaxoSmithKlineSee more
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment - PfizerSee more
Chronic bronchitis
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) - PILASTER - Chiesi Farmaceutici S.p.A.See more
Chronic obstructive pulmonary disease
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) - PILASTER - Chiesi Farmaceutici S.p.A.See more
Diffuse sclerosis
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms - VITALISScE™ - Boehringer IngelheimSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Lupus
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus - TOPAZ-2 - BiogenSee more
Prurigo nodularis
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) - TRuE-PN1 - Incyte CorporationSee more
Rare diseases
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease. - Hoffmann-La RocheSee more
